1-6 of 6
Ellen C Dompeling
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Clinical Trials & Observations
Lina van der Straten, Claudia A. M. Stege, Sabina Kersting, Kazem Nasserinejad, Julie Dubois, Johan A. Dobber, Clemens H. M. Mellink, Anne-Marie F. van der Kevie-Kersemaekers, Ludo M. Evers, Fransien de Boer, Harry R. Koene, John Schreurs, Marjolein van der Klift, Gerjo A. Velders, Ellen van der Spek, Hanneke M. van der Straaten, Mels Hoogendoorn, Michel van Gelder, Eduardus F. M. Posthuma, Hein P. J. Visser, Ilse Houtenbos, Cecile A. M. Idink, Djamila E. Issa, Ellen C. Dompeling, Henk C. T. van Zaanen, J. Hendrik Veelken, Henriette Levenga, Lidwine W. Tick, Wim E. Terpstra, Sanne H. Tonino, Peter E. Westerweel, Anton W. Langerak, Arnon P. Kater, Mark-David Levin
Journal: Blood
Blood (2023) 142 (13): 1131–1142.
https://doi.org/10.1182/blood.2023020195
Published: 2023
Includes: Supplemental data
Journal Articles

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Clinical Trials & Observations
Moritz Fürstenau, Yvonne J. Thus, Sandra Robrecht, Clemens H. M. Mellink, Anne-Marie van der Kevie-Kersemaekers, Julie Dubois, Julia von Tresckow, Michaela Patz, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar da Cunha-Bang, Christof Schneider, Christian Bjoern Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Nösslinger, Michael Baumann, Holger Hebart, Tobias Gaska, Josien C. Regelink, Ellen C. Dompeling, Vesa Lindström, Gunnar Juliusson, Anouk Widmer, Jeroen Goede, Neta Goldschmidt, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Marcel Spaargaren, Eric Eldering, Stephan Stilgenbauer, Carsten U. Niemann, Michael Hallek, Barbara Eichhorst, Karl-Anton Kreuzer, Arnon P. Kater
Journal: Blood
Blood (2023) 142 (5): 446–459.
https://doi.org/10.1182/blood.2023019634
Published: 2023
Includes: Supplemental data
Journal Articles

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Moritz Furstenau, Yvonne Thus, Sandra Robrecht, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Julie M.N. Dubois, Julia Von Tresckow, Michaela Patz, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar Da Cunha-Bang, Christof Schneider, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Michael Baumann, Thomas Noesslinger, Josien Regelink, Ellen C Dompeling, Vesa Lindström, Gunnar Juliusson, Anouk Widmer, Jeroen Simon Goede, Neta Goldschmidt, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Stephan Stilgenbauer, Eric Eldering, Carsten Utoft Niemann, Michael Hallek, Barbara Eichhorst, Karl-Anton Kreuzer, Arnon P. Kater
Journal: Blood
Blood (2022) 140 (Supplement 1): 842–845.
https://doi.org/10.1182/blood-2022-164786
Published: 2022
Journal Articles

Time-Limited Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Who Have Undetectable MRD - Primary Analysis from the Randomized Phase II Vision HO141 Trial

Carsten Utoft Niemann, Julie Dubois, Christian Brieghel, Sabina Kersting, Lisbeth Enggaard, Gerrit J Veldhuis, Rogier Mous, Clemens Mellink, Johan A Dobber, Christian Bjørn Poulsen, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C Dompeling, Juha Ranti, Mattias Mattsson, Mar Bellido, Kazem Nasserinejad, Hoa Thi Tuyet Tran, Mark-David Levin, Arnon P. Kater
Journal: Blood
Blood (2021) 138 (Supplement 1): 69.
https://doi.org/10.1182/blood-2021-148630
Published: 2021
Journal Articles

Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia

Clinical Trials & Observations
Carsten U. Niemann, Mark-David Levin, Julie Dubois, Sabina Kersting, Lisbeth Enggaard, Gerrit J. Veldhuis, Rogier Mous, Clemens H. M. Mellink, Johan A. Dobber, Christian B. Poulsen, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C. Dompeling, Juha Ranti, Mattias Mattsson, Mar Bellido, Hoa T. T. Tran, Kazem Nasserinejad, Arnon P. Kater
Journal: Blood
Blood (2021) 137 (8): 1117–1120.
https://doi.org/10.1182/blood.2020008608
Published: 2021
Includes: Supplemental data
Journal Articles

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) - 15-Month Safety, Response and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 Trial

Carsten Utoft Niemann, MD PhD, Julie Dubois, Sabina Kersting, MD PhD, Lisbeth Enggaard, MD, Gerrit J Veldhuis, Rogier Mous, MD PhD, Clemens Mellink, PhD, Johan A Dobber, Christian Bjørn Poulsen, MD, Henrik Frederiksen, MD Prof, Ann Janssens, Ida Schjødt, MD PhD, Ellen C Dompeling, Juha Ranti, Mattias Mattsson, MD, Mar Bellido, Hoa T Tran, Kazem Nasserinejad, Mark-David Levin, MD PhD, Arnon P. Kater, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4292.
https://doi.org/10.1182/blood-2019-124377
Published: 2019